A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
Key facts
- Who runs it
- SymBio Pharmaceuticals
- Where
- Chicago, Cincinnati, Durham, Houston, Los Angeles, Memphis, Omaha, Philadelphia, San Francisco, and Seattle, United StatesSee the 10 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 53 people enrolled
- Started
- 16 Aug 2021
- Ended
- 15 May 2025
- Type of study
- Interventional, 7 groups
- Treatments tested
- BCV
- Record updated
- 11 August 2026
Who can take part
- Age
- 2 months and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Male or female, aged 2 months and older at the time of informed consent
- AdV DNA viremia >10,000 copies/mL from a single sample, or 2 samples greater than 48 hours apart with the second result higher than the first and both greater than 1000 copies/mL, from the data obtained from the designated central virology laboratory of the local laboratory using the blood sample(s) collected informed consent has been obtained and within 7 days prior to Day 1 (AdV DNA viremia results collected within the 7 day window, but prior to consent may be used if the Informed Consent Form (ICF) signed by the subject provides approval) . CMV viremia with or without evidence of tissue invasive CMV disease. For laboratory results that are generated in units other than copies/mL or IU/mL, please refer to the testing laboratory for guidance on the appropriate conversion calculation
- Either (a) have disseminated AdV disease or (b) have an underlying immunocompromised state, and have asymptomatic AdV infection or localized AdV disease
- In the judgment of the investigator, be in a serious condition to be treated with intravenous cidofovir for AdV
Who cannot take part
- NIH/NCI CTCAE (United States [US] National Institutes of Health [NIH]/National Cancer Institute) Grade 2 or higher diarrhea (i.e., increase of ≥ 4 stools per day over usual pre-transplant stool output) within 7 days prior to Day 1
- NIH Stage 4 acute GVHD of the skin (i.e., generalized erythroderma with bullous formation) within 7 days prior to Day 1
- NIH Stage 2 or higher acute GVHD of the gut (i.e., diarrhea >556 mL/m2/day for pediatric subjects [or >1000 mL/day for young adults as applicable, at centers in the United States only], or severe abdominal pain with or without ileus) within 7 days prior to Day 1
- NIH Stage 2 or higher acute GVHD of the liver function (i.e., bilirubin >3 mg/dL [SI: >51 μmol/L]) within 7 days prior to Day 1
- Subjects who weigh ≥120 kg
Where in United States
- Chicago, IllinoisHospital not named in the registry
- Cincinnati Children's Hospital Medical CenterCincinnati, United States
- Durham, North CarolinaHospital not named in the registry
- MD Anderson Cancer CenterHouston, United States
- Los Angeles, CaliforniaHospital not named in the registry
- St. Jude Children's Research HospitalMemphis, United States
- University of Nebraska Medical CenterOmaha, United States
- Philadelphia, PennsylvaniaHospital not named in the registry
- San Francisco, CaliforniaHospital not named in the registry
- Seattle, WashingtonHospital not named in the registry
About the trial
What the trial wants to find out
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
The 7 groups in the trial
- BCV 0.2mg/kg BIWTreatment being tested
BCV: 0.2 mg/kg administered as a continuous IV infusion over 2 hours
Treatment: BCV
- BCV 0.3mg/kg BIWTreatment being tested
BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours
Treatment: BCV
- BCV 0.4 mg/kg BIWTreatment being tested
BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours
Treatment: BCV
- BCV 0.4 mg/kg QWTreatment being tested
BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours
Treatment: BCV
- 0.4 mg/kg BIWTreatment being tested
BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours
Treatment: BCV
- 0.5 mg/kg BIWTreatment being tested
BCV: 0.5 mg/kg administered as a continuous IV infusion over 2 hours
Treatment: BCV
- 0.6 mg/kg BIWTreatment being tested
BCV: 0.6 mg/kg administered as a continuous IV infusion over 2 hours
Treatment: BCV
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection or Cytomegalovirus Infection
- Record updated
- 11 August 2026